Natco Pharma has signed a non-exclusive license agreement with the Medicines Patent Pool (MPP), Switzerland to manufacture and sell Molnupi...

Experience with the Omicron variant so far makes clear that while vaccines are critical for reducing the virulence of the disease, therapie...

Data from Pfizer's clinical trial showed its two-drug antiviral regimen was 90% effective in preventing hospitalizations and deaths in pati...

The federal government said it backed a recommendation of a national advisory board on immunizations that all adults above 50 should receiv...

The analysis of latest data on efficacy is much less than the previous interim analysis announced by the company which was based on data fr...

And this is despite Dr Reddy’s, one of India’s largest drugmakers, gearing to export Sputnik shots next year and expecting regulatory nod t...

The voluntary licensing agreement between Pfizer and the MPP will allow the United Nations-backed group to grant sub-licenses to qualified ...

The MHRA recommended the use of Covid-19 drug molnupiravir as soon as possible following a positive Covid-19 test and within five days of s...

The risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as s...

The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe...

Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...

The two Indian drugmakers, Aurobindo Pharma and MSN Laboratories plan to continue late-stage trails of the drug for those with mild COVID-1...

The pills are meant for people who are sick with COVID but are not in the hospital.

MSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero f...

MSD has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufactur...

In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, incl...